Bank helps Reacta with global push

PHARMACEUTICAL manufacturer has launched two new products and unveiled plans to extend its global reach.

- SION BARRY Business editor

Deeside-based Reacta Healthcare, whose growth potential has been backed by the Development Bank of Wales with nearly £3m of equity investment, is transforming the way food allergies are diagnosed.

Its Oral Food Challenge (OFC) products are shipped to more than 300 clinical trials sites worldwide.

Reacta Healthcare, which employs 80, is recognised as the only OFC supplier working to Good Manufacturing Practice (GMP) standards and operating worldwide supplying global clinical trials.

With demand for food allergy diagnostics rising sharply - driven by an estimated 250 million people worldwide living with food allergies - Reacta Healthcare is helping meet a critical global need. In the UK alone, around 8.5% of the population is affected.

Founded on technology developed at the University of Manchester and spun out by professors Ashley Woodcock and Claire Mills, Reacta Healthcare relocated to north Wales in 2018 to expand production.